01532nas a2200457   4500000000100000000000100001000000100002008004100003653004700044653001500091653002800106653003200134653001900166653002800185653004700213653001100260653005600271653005200327653004400379653002600423653005800449653003100507653002800538653003000566653001700596653003900613653002700652100001600679700001400695700001500709700001400724700001700738700001200755700001500767700001700782700001500799245020800814250001501022490000601037020003101043       2022                            d10a*Acute Coronary Syndrome/diagnosis/therapy10aAdolescent10aAspirin/adverse effects10aClopidogrel/adverse effects10aCohort Studies10aDinucleoside Phosphates10aHemorrhage/chemically induced/epidemiology10aHumans10a*Percutaneous Coronary Intervention/adverse effects10aPlatelet Aggregation Inhibitors/adverse effects10aPrasugrel Hydrochloride/adverse effects10aRetrospective Studies10a*ST Elevation Myocardial Infarction/diagnosis/therapy10aTicagrelor/adverse effects10aacute coronary syndrome10aElectronic Health Records10aepidemiology10apercutaneous coronary intervention10apharmacology, clinical1 aM. Pufulete1 aJ. Harris1 aK. Pouwels1 aB. Reeves1 aD. Lasserson1 aY. Loke1 aA. Mumford1 aK. Mahadevan1 aT. Johnson00aReal-world bleeding in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) and prescribed different combinations of dual antiplatelet therapy (DAPT) in England  a2022/08/130 v9  a2053-3624 (Print)2053-3624